(Q35557360)

8 August 2017

1 reference

title

Pancreatic beta-cell loss and preservation in type 2 diabetes (English)

1 reference

8 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

20 March 2024

author name string

Thomas A. Buchanan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14553865

20 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14553865

20 March 2024

publication date

1 January 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0149291803802412?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

https://api.elsevier.com/content/article/PII:S0149291803802412?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

20 March 2024

published in

Clinical Therapeutics

1 reference

8 August 2017

25 Suppl B

1 reference

8 August 2017

B32-46

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The continuing epidemics of obesity and diabetes in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Mechanisms of fatty acid-induced inhibition of glucose uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Is insulin resistance the principal cause of type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Accurate assessment of beta-cell function: the hyperbolic correction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Early disturbances in insulin secretion in the development of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Circulating proinsulin in patients with maturity onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Control of pulsatile insulin secretion in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Pathogenesis of NIDDM. A balanced overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Relationship Between Fasting Plasma Insulin Level and Resistance to Insulin-Mediated Glucose Uptake in Normal and Diabetic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Relationship of islet function to insulin action in human obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

THE RELATION OE DIABETES MELLITUS TO LESIONS OF THE PANCREAS. HYALINE DEGENERATION OF THE ISLANDS OE LANGERHANS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Longitudinal studies on the development of diabetes in individual Macaca nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980241-2

7 January 2021

Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide

47

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Defective acute insulin secretion in diabetics. Differences between normal weight and obese subjects

20 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans

20 March 2024

56

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Adaptation of B and A cell function during prolonged glucose infusion in human subjects

20 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

20 March 2024

60

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Regulation of fatty acid homeostasis in cells: novel role of leptin

20 March 2024

64

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Amyloid peptides are toxic via a common oxidative mechanism

20 March 2024

78

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation

20 March 2024

87

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone

20 March 2024

100

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80241-2

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference